Severe acute respiratory syndrome (SARS) 
In early 2003, public health authorities, physicians and scientists around the world are struggling to cope with a severe and rapidly spreading new disease in humans, severe acute respiratory syndrome, or SARS. This appears to be the first severe and easily transmissible new disease to emerge in the 21st century. Severe Acute Respiratory Syndrome (SARS) was first identified in Viet Nam on February 28, 2003, when Dr Carlo Urbani, an epidemiologist from the Hanoi WHO office examined a patient with a severe form of pneumonia for which no etiology could be found. On March 10, 2003, 22 hospital workers in Hanoi French Hospital were ill with a similar acute respiratory syndrome, and by March, 11 similar outbreaks had been reported among hospital workers in Hong Kong. 1, 2 Despite some positive signs that imported cases are not spreading further, outbreaks in China, Canada, Hong Kong, Hanoi, and Singapore have taken root in hospitals and beyond, and give rise to considerable concern. One of the most alarming features of SARS in these areas is its rapid spread in hospitals, where it has affected a large number of previously healthy health care workers. Many require intensive care, placing a huge strain on hospital facilities and staff. In countries, such as Canada, where cases occurred 60 before WHO issued its global alert, SARS is continuing to spread despite the introduction of strict patient isolation and excellent infection control. In this article some SARS epidemiological data in Indonesia will also presented. 
CASE DEFINITION

Exclusion Criteria
A case should be excluded if an alternative diagnosis can fully explain their illness.
Reclassification of Cases
As SARS is currently a diagnosis of exclusion, the status of a reported case may change over time. A patient should always be managed as clinically appropriate, regardless of their case status.
-A case initially classified as suspect or probable, for whom an alternative diagnosis can fully explain the illness, should be discarded after carefully considering the possibility of co-infection.
-A suspect case who, after investigation, fulfils the probable case definition should be reclassified as "probable".
-A suspect case with a normal CXR should be treated, as deemed appropriate, and monitored for 7 days. Those cases in whom recovery is inadequate should be re-evaluated by CXR.
-Those suspect cases in whom recovery is adequate but whose illness cannot be fully explained by an alternative diagnosis should remain as "suspect".
-A suspect case who dies, on whom no autopsy is conducted, should remain classified as "suspect". However, if this case is identified as being part of a chain transmission of SARS, the case should be reclassified as "probable".
-If an autopsy is conducted and no pathological evidence of RDS is found, the case should be "discarded". 
ETIOLOGY
Based on conclusive proof, from animal trials, a new coronavirus, discovered by WHO collaborative group is the agent that causes SARS.
With the cause of SARS is proven, network scientists are giving top priority to the development of better diagnostic tests. 
CASE FATALITY RATIO
WHO estimates that the case fatality ratio of SARS ranges from 0% to 50% depending on the age group affected, with an overall estimate of case fatality of 14% to 15%.The likelihood of dying from SARS in a given area has been shown to depend on the profile of the cases, including the age group most affected and the presence of underlying disease. Based on data, the case fatality ratio is estimated to be less than 1% in persons aged 24 years or younger, 6% in persons aged 25 to 44 years, 15% in persons aged 45 to 64 years, and greater than 50% in persons aged 65 years and older .The estimates of the case fatality ratio range from 11% to 17% in Hong Kong, from 13% to 15% in Singapore, from 15% to 19% in Canada, and from 5% to 13% in China. 6 A more accurate and unbiased estimation of case fatality for SARS can be obtained with a survival analysis method. This method relies on detailed individual data on the time from illness onset to death or full recovery, or time since illness onset for current cases. Using this method, WHO estimates that the case fatality ratio is 14% in Singapore and 15% in Hong Kong. In Viet Nam, where SARS has been contained and measurement is more straightforward, case fatality was comparatively low, at 8%. One explanation for this is the large number of total cases that occurred in younger, previously healthy health care workers. Table 3 showed the travel history of patients, which showed that all probable cases has a travel history from Singapore, while 71.5% suspect cases were also traveled from Singapore and the remaining 28.5% cases were traveled to China before get symptoms related to SARS. Table 4 showed location where the patients stayed / treated. All of these 103 patients were diagnoses or treated at 26 hospitals throughout Indonesia. Table 5 showed the symptom from the patients. Data showed that all suspect and probable cases experienced fever, and all probable cases also have cough and shortness of breath. On the other hand, only 57.14% suspect cases had a cough complain and 28,57% suspect cases complain of shortness of breath.
No more SARS cases were reported in Indonesia after July 9. How will be SARS progress in the future will is a subject of discussion among scientist, and we will have to wait and be prepared for any development may occur. 
